Federated Hermes’s C4 Therapeutics CCCC Stock Holding History

Federated Hermes’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.77K	Hold	1,878	–	–	﹤0.01%	1865
2026 Q1	$4.94K	Buy	+1,878	New	+$4.42K	﹤0.01%	1893
2025 Q2	–	Sell	-1,069	Closed	-$1.71K	–	2077
2025 Q1	$1.71K	Buy	+1,069	New	+$3.19K	﹤0.01%	1961
2024 Q3	–	Sell	-316	Closed	-$1.46K	–	2070
2024 Q2	$1.46K	Buy	+316	New	+$1.89K	﹤0.01%	1922
2023 Q4	–	Sell	-3,141	Closed	-$5.84K	–	2061
2023 Q3	$5.84K	Buy	3,141 +2,739	+681%	+$8.35K	﹤0.01%	1872
2023 Q2	$1.11K	Sell	402 -3,055	-88%	-$9.82K	﹤0.01%	2025
2023 Q1	$10.9K	Sell	3,457 -7,614	-69%	-$44.8K	﹤0.01%	1866
2022 Q4	$65.3K	Buy	11,071 +10,076	+1,013%	+$83.5K	﹤0.01%	1689
2022 Q3	$9K	Buy	+995	New	+$10.3K	﹤0.01%	1840
2022 Q1	–	Sell	-41,897	Closed	-$1.35M	–	2209
2021 Q4	$1.35M	Sell	41,897 -16,715	-29%	-$661K	﹤0.01%	1166
2021 Q3	$2.62M	Buy	+58,612	New	+$2.51M	0.01%	974
2021 Q2	–	Sell	-38,975	Closed	-$1.44M	–	2218
2021 Q1	$1.44M	Buy	+38,975	New	+$1.55M	﹤0.01%	1237

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Federated Hermes's CCCC Position: Q2 2026 in Review

Federated Hermes held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 1,878 shares worth $8.77K. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

Federated Hermes first reported a position in CCCC in Q1 2021 and has held it in 12 quarters since. The position peaked at $2.62M in Q3 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Federated Hermes held 1,878 shares of C4 Therapeutics worth $8.77K as of Q2 2026.
Federated Hermes left its C4 Therapeutics share count unchanged in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1865 holding.
Federated Hermes first reported a position in C4 Therapeutics in Q1 2021 and has held it in 12 quarters since.
Federated Hermes's C4 Therapeutics position peaked at $2.62M in Q3 2021.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.